Publications by authors named "I M Bondarenko"
The randomized phase III FALCON trial demonstrated significant improvement in progression-free survival (PFS) with fulvestrant versus anastrozole in postmenopausal women with endocrine therapy-naïve, hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. Herein, the prespecified final overall survival (OS) analysis is reported. After the primary PFS analysis, data were collected on survival, serious adverse events, and health-related quality of life.
View Article and Find Full Text PDFBackground: Given the many nicotine and tobacco products in use, studies of the interdependence of use patterns and transitions are needed.
Methods: Using Waves 1-4 of the PATH Study, we analyzed latent transitions among adults who ever regularly used nicotine or tobacco products at Wave 1 to identify latent use states (n = 12,358) and estimated one-wave transition probabilities. Multinomial logistic regression identified demographic factors associated with transitions.
Background: In metastatic colorectal cancer (mCRC), improvements in survival from combining leucovorin/fluorouracil/oxaliplatin/irinotecan (FOLFOXIRI) with bevacizumab have come at the risk of increased rates of high-grade toxicities. Trilaciclib is indicated to decrease the incidence of chemotherapy-induced myelosuppression in patients receiving standard-of-care chemotherapy for extensive-stage small cell lung cancer.
Methods: Patients with untreated mCRC were randomly assigned 1:1 to trilaciclib (n = 164) or placebo (n = 162) prior to FOLFOXIRI/bevacizumab for up to 12 cycles (induction), followed by trilaciclib or placebo prior to fluorouracil/leucovorin/bevacizumab (maintenance).
Management of Tricuspid Atresia With Normally Related Great Arteries and Left-Sided Obstruction.
World J Pediatr Congenit Heart Surg
November 2024
Article Synopsis
- Tricuspid atresia (TA) is a heart condition affecting infants and is the second most common type of functionally univentricular heart, with rare cases of left ventricular outflow tract obstruction (LVOTO) in patients who have normally related great arteries.
- A study involving 445 patients with Type I TA showed that 3% of infants needed interventions for LVOTO, and most of those who underwent surgical procedures had promising outcomes.
- The long-term survival rate for these infants was estimated at 79% over 20 years, indicating that timely surgical management can lead to successful interventions and good heart function later in life.
Article Synopsis
- - The study aimed to assess the safety, tolerability, pharmacokinetics, and effectiveness of sasanlimab, a monoclonal antibody targeting PD-1, in treating participants with advanced cancers, including a focus on non-small-cell lung cancer.
- - An open-label design was used, with Phase Ib involving dose escalation and expansion in Asian participants, while Phase II included a global trial randomizing participants to receive either 300 mg every 4 weeks or 600 mg every 6 weeks.
- - Results indicated that Phase Ib had no dose-limiting toxicities and Phase II showed manageable grade 3 treatment-related adverse events, with confirmed response rates of 26.8% and 15.0%